东方生物(688298) - 2025 Q4 - 年度业绩预告

Financial Performance Expectations - The company expects a net loss attributable to shareholders of approximately -523 million yuan for the year 2025[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be -558 million yuan[4] - In the same period last year, the net profit attributable to shareholders was -529 million yuan, with a total profit of -585 million yuan[5] - The company reported a loss per share of -2.69 yuan in the previous year[5] Reasons for Expected Loss - The main reason for the expected loss is significant investments in strategic development across various technology platforms, along with exchange losses and reduced interest income[6] Uncertainties and Risks - The company has not identified any major uncertainties affecting the accuracy of this earnings forecast as of the announcement date[8] - The financial data in the earnings forecast has not been audited by a registered accountant[7] - The preliminary financial data provided is subject to change and will be finalized in the audited annual report for 2025[9] - The company emphasizes the importance of investors being aware of investment risks related to this forecast[9] Announcement Details - The announcement was made by the Board of Directors on January 30, 2026[11]